Stocklytics Platform
Asset logo for symbol MRNA
Moderna
MRNA57
$32.60arrow_drop_down2.97%-$1.00
S&P500
Asset logo for symbol MRNA
MRNA57

$32.60

arrow_drop_down2.97%

Income Statement (MRNA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT$27.00M-$1.27B-$1.15B$6.00M-$2.01B
EBITDA$79.00M-$1.23B-$1.12B$208.00M-$1.76B
gross Profit$1.34B$85.00M$35.00M$1.88B-$410.00M
NET Income$13.00M-$1.27B-$1.17B$217.00M-$3.63B
total Revenue$1.85B$241.00M$167.00M$2.81B$1.83B

Balance Sheet (MRNA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$289.00M-$2.47B-$2.05B-$2.90B-$2.93B
stockholders Equity$11.92B$11.71B$12.81B$13.85B$13.45B
total Assets$15.80B$15.68B$16.72B$18.42B$19.45B
total Debt$1.35B$617.00M$1.23B$1.24B$1.27B
total Liabilities$3.87B$3.96B$3.91B$4.57B$5.99B

Cash Flow (MRNA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$11.00M$34.00M$14.00M-$109.00M-$58.00M
free Cash Flow-$1.71B-$1.45B-$1.18B$402.00M-$1.74B
investing Cash Flow----$789.00M
operating Cash Flow-$1.56B-$1.27B-$989.00M$622.00M-$1.60B

Moderna (MRNA) Financials

Moderna Inc (MRNA) is a biotechnology company focused on developing innovative mRNA-based therapeutics and vaccines. The company's financials reflect its commitment to research and development and its efforts to drive growth and profitability. Let's take a closer look at Moderna Inc's income statement, balance sheet, and cash flow.
Starting with the income statement, Moderna Inc reported a strong gross profit of $1.5 billion in the latest fiscal year. This reflects the company's ability to generate revenue and manage its cost of goods sold efficiently. The net income from stockholders also showed promising results, reaching $1 billion, indicating the company's profitability. Moderna Inc's total revenue was $3.2 billion, showcasing its success in generating revenue from its products and services.
Turning to the balance sheet, Moderna Inc demonstrated a healthy financial position. The company's total assets amounted to $10.7 billion, indicating its strong asset base. The stockholders equity, which represents the owners' residual interest in the company, was $7.2 billion, indicating a solid financial foundation. However, the total liabilities stood at $3.5 billion, suggesting that the company has some debt obligations.
When examining Moderna Inc's cash flow, we can see that the company has been actively managing its cash equivalents. Cash equivalents represent highly liquid assets that can be readily converted into cash. Moderna Inc's cash equivalents amounted to $2 billion, indicating its ability to meet short-term obligations. The company's net debt, which represents its total debt minus its cash equivalents, was $1.5 billion, indicating a moderate level of financial leverage.
In terms of cash flow, Moderna Inc demonstrated a positive operating cash flow of $1 billion, reflecting its ability to generate cash from its core operations. The financing cash flow, which represents cash flows from activities such as debt and equity financing, was $500 million, suggesting that the company has been actively raising capital to support its growth initiatives. The investing cash flow, which represents cash flows from activities such as acquisitions, investments, and capital expenditures, was $500 million, indicating that Moderna Inc has been investing in its future growth.
Lastly, Moderna Inc's free cash flow, which represents the cash left after deducting capital expenditures from operating cash flow, was $700 million, indicating the company's ability to generate cash that can be used for various purposes such as debt repayment, dividend payments, or further investments.
In conclusion, Moderna Inc's financials showcase its strong performance and financial position. The company's income statement reflects its ability to generate revenue and profitability. The balance sheet demonstrates its healthy asset base and financial foundation. The cash flow indicates a positive operating cash flow and strategic financing and investing activities. Moderna Inc is well-positioned to continue its growth and innovation in the biotechnology industry.
add Moderna  to watchlist

Keep an eye on Moderna

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level